Growth Hormone Secretagogues Explained: GHRH Analogs vs GHRPs

"Growth hormone secretagogue" is a category label, not a single compound — it covers any research compound that stimulates the pituitary to release growth hormone (GH). The category splits into two structurally and mechanistically distinct families, and understanding the split explains why they're so often studied together. For a deep dive on the synergy between the two families, see CJC-1295 and Ipamorelin; for one specific GHRH analog, see Tesamorelin's mechanism.

Two Families, Two Receptors

Pituitary GH secretion is controlled by at least two convergent hypothalamic inputs, and research secretagogues are generally built to mimic one or the other:

• GHRH analogs (Tesamorelin, CJC-1295, Sermorelin) — synthetic versions of growth hormone-releasing hormone, acting on the GHRH receptor via the cAMP signaling pathway.
• GHRPs / ghrelin mimetics (Ipamorelin, and older-generation compounds like GHRP-2 and GHRP-6) — synthetic ghrelin-receptor (GHS-R1a) agonists, signaling through a separate calcium-based pathway.

GHRH Analogs: Modeling Endogenous Tone

GHRH analogs are typically modified fragments of native GHRH — for example, Tesamorelin carries a trans-3-hexenoic acid modification, and CJC-1295 carries amino-acid substitutions that resist DPP-4 degradation. Both extend the parent hormone's short natural half-life while preserving its ability to bind the GHRH receptor and activate the cAMP pathway. In research models, these compounds are used to model sustained or elevated GHRH-receptor tone.

GHRPs: Modeling Pulsatile Signaling

Ghrelin-mimetic GHRPs act on GHS-R1a through a distinct, calcium-based signaling cascade. Earlier-generation GHRPs (GHRP-6, GHRP-2) are potent GH secretagogues in animal models but also produce dose-dependent increases in ACTH, cortisol, and prolactin — off-target pituitary effects that complicate interpreting a GH-axis study. Ipamorelin's defining characteristic in the original pharmacology literature is that it stimulates GH release with minimal corresponding rise in those other hormones, which is why it's the GHRP most frequently chosen for comparative secretagogue research today.

Why the Two Are Often Combined in Research

Because GHRH-receptor and GHS-R1a signaling engage different intracellular cascades, combining a representative from each family is a recurring experimental design in GH secretagogue pharmacology. A controlled human pharmacodynamic study found that low-dose ghrelin combined with GHRH produced a GH response significantly greater than the additive sum of either alone — a synergistic, not merely additive, result. That mechanistic rationale is why CJC-1295 + Ipamorelin is a common pairing in comparative research designs; see the dedicated synergy article for the full breakdown of that specific pairing.

Supply and Storage

Research-grade secretagogues in either family are typically supplied as lyophilized powders. Purity should be verified by HPLC with sequence identity confirmed by mass spectrometry, and reconstituted solutions should be refrigerated and used within the window on the COA — see how to reconstitute research peptides.

Research Use Only

All compounds discussed here are sold and studied strictly for laboratory and preclinical research, not for human or animal administration. Every lot we ship is third-party HPLC tested and lot-tracked — confirm any lot on our verification page.